Ovoca Presents at BIO-Europe Spring® 2019, Vienna
Ovoca's Chief Executive Officer, Kirill Golovanov, along with Dr. Nemenov and Mr. Wiltshire, recently attended and presented Ovoca Bio at the 13th Annual International Partnering Conference, BIO-Europe Spring®, at the Messe Wien Exhibition and Congress Center, Vienna, Austria between March 25-27th, 2019.
They discussed with potential partners and collaborators the strong progress made with Libicore (BP-101), including the exciting Phase 3 results announced in a press release at the beginning of the conference, and the development plans for the rest of 2019.
The team had a busy schedule, meeting with a combination of pharma/biotech companies from North America, Europe and East Asia, international investors, and current and future contract supplier organizations.
Strong enthusiasm for our lead program was shown and follow-up action with many that we met with, is in hand.
The Company recognizes the importance of building up its international visibility and establishing long and lasting relationships with the diverse biotech community; forums like BIO are very helpful in facilitating that goal.
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
IVIX, a Russian‐incorporated company, was formed in 2012 and since that time has sought to develop and subsequently commercialize a proprietary drug candidate, BP-101 (known as "Libicore"), for the treatment of female sexual dysfunction. Libicore is a novel synthetic peptide, administered through a nasal spray. Clinical studies completed to-date have demonstrated statistically significant efficacy in the treatment of a major form of female sexual dysfunction. So far, IVIX has reached and completed Phase III clinical studies in Russia for Libicore. It now intends to seek approval for the marketing of Libicore in the Russian market, as well seek to expand its use internationally.